DELTA-neuroimaging.

Neuroimaging of vulnerability for recurrence in major depressive disorder. A prospective neuroimaging study investigating neurobiological and psychoneuroendocrinological mechanisms underlying recurrent Major Depressive Disorder and predicting recurrence.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27041

Enrollment

100

Registered

2012-12-24

Start date

2011-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Apart from mood-induction during assessment no interventions applied.

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS: 1. Age 35-65 yr; 2. Both sexes; 3. ≥2 MDD episodes according to a structured interview for DSM-IV (SCID); 4. In stable remission defined as a Hamilton depression rating scale (HDRS) ≤7 and Inventory for depressive symptomatology (IDS-SR) ≤14 for at least 10 weeks. CONTROLS: 1. Matched for age, sex and years of education; 2. IDS-SR ≤14.

Exclusion criteria

Exclusion criteria: PATIENTS: 1. Current diagnosis of alcohol or drug dependence, psychotic or bipolar disorder, predominant anxiety disorder; 2. Standard fMRI exclusion criteria (claustrophobia, implanted metal objects in the bodies); 3. Electroconvulsive therapy within two months before scanning; 4. A history of head trauma or neurological disease, severe general physical illness. CONTROLS: 1. Personal (assessed by SCID) or 1st degree relative with psychiatric disorder; 2. Current diagnosis of alcohol or drug dependence; 3. Standard fMRI exclusion criteria (claustrophobia, implanted metal objects in the bodies); 4. A history of head trauma or neurological disease, severe general physical illness.

Design outcomes

Primary

Measure	Time frame
Prospective Recurrence of MDD during 2.5 years of follow-up.	—

Secondary

Measure	Time frame
Clinical: Retrospective Recurrence of MDD during 2.5 years of follow-up. Neuroimaging: sMRI, DTI, fMRI (reward-aversive paradigm, emotion regulation task, resting state [before/after mood-induction], Cued Emotional Conflict Task), MRS. Blood & Saliva: Poly Unsaturated Fatty Acids, Brain Derived Neurotrophic Factor, DNA and mRNA Genetics, Salivary cortisol and DHEA-s. Experience Sampling Method: Daily positive and negative affect measurements during 6 days.	—

Measure

Time frame

Clinical: Retrospective Recurrence of MDD during 2.5 years of follow-up. Neuroimaging: sMRI, DTI, fMRI (reward-aversive paradigm, emotion regulation task, resting state [before/after mood-induction], Cued Emotional Conflict Task), MRS. Blood & Saliva: Poly Unsaturated Fatty Acids, Brain Derived Neurotrophic Factor, DNA and mRNA Genetics, Salivary cortisol and DHEA-s. Experience Sampling Method: Daily positive and negative affect measurements during 6 days.

—

Contacts

Public ContactH.G. Ruhe

Academic Medical Center (AMC), Program for Mood Disorders, Department of Psychiatry, P.O. Box 22660

H.G.Ruhe@AMC.UvA.NL+31 (0)20 5662088

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)